Events

Vienna, Austria – October 7 – 11, 2017 – EACTS – European Association for Cardio-Thoracic Surgery[Read More]

Press Releases

Austin, TX – March 22, 2017 – HAART 200 Aortic Annuloplasty Device Receives FDA clearance[Read More]

Austin, TX – June 14, 2017 – U.S. Pilot Launch and First Commercial Use of the HAART 300 [Read More]

Austin, TX – March 22, 2017 – HAART 300 Aortic Annuloplasty Device Receives FDA clearance[Read More]

Austin, TX – Oct 11, 2016 – Direct De Novo Application to FDA for the HAART 300[Read More]

Austin, TX – May 16, 2016 – European Commercialization of the HAART 300[Read More]

Austin, TX – March 8, 2016 – HAART 300 Receives CE Mark Approval[Read More]

News and Events

/Tag:News

BioStable Science & Engineering, Inc. News

HAART 200 Receives FDA Clearance

BioStable Science & Engineering Announces FDA Clearance of the HAART™ 200 Aortic Annuloplasty Device for Bicuspid Aortic Valve Repair Austin, TX – August 15, 2017 - BioStable Science & Engineering, Inc. announced today it has received FDA market clearance for the HAART 200 Aortic Annuloplasty Device, the first and only annuloplasty device designed specifically for [...]

August 15th, 2017|News, Press Release|

First Commercial Use of the HAART 300 in US

BioStable Science & Engineering Announces U.S. Pilot Launch and First Commercial Use of the HAART™ 300 Aortic Annuloplasty Device Austin, TX – June 14, 2017 - BioStable Science & Engineering, Inc. HAART 300 Aortic Annuloplasty Device, announced today the first commercial uses of the HAART 300 Aortic Annuloplasty Device in the U.S. by doctors at [...]

June 14th, 2017|News, Press Release|

HAART 300 Receives FDA Clearance

BioStable Science & Engineering announces FDA clearance of the HAART™ 300 Aortic Annuloplasty Device Austin, TX – March 22, 2017 - BioStable Science & Engineering, Inc. announced today it has received FDA market clearance for the HAART 300 Aortic Annuloplasty Device, the first commercially available internal annuloplasty device designed for aortic valve repair. BioStable expects [...]

March 22nd, 2017|News, Press Release|

De Novo Application to FDA for the HAART 300

BioStable Science & Engineering Completes Direct De Novo Application to FDA for the HAART™ 300 Aortic Annuloplasty Device Austin, TX – October 11, 2016 - BioStable Science & Engineering, Inc. announced today that it has completed a direct de novo application to the U.S. Food and Drug Administration (FDA) for Class II designation of the [...]

October 11th, 2016|News, Press Release|

European Commercialization of the HAART 300

BioStable Science & Engineering Initiates European Commercialization of the HAART™ 300 Aortic Annuloplasty Device First commercial implantation performed by Dr. Domenico Mazzitelli, at the German Heart Center Munich Austin, TX – May 16, 2016 - BioStable Science & Engineering, Inc. announced today that the first commercial implantation of its HAART 300 Aortic Annuloplasty Device was [...]

May 16th, 2016|News, Press Release|

HAART 300 Receives CE Mark Approval

BioStable Science & Engineering Announces CE Mark Approval for the HAART 300 Aortic Annuloplasty Device Patented aortic valve repair technology offers a new alternative to aortic valve replacement Austin, TX – March 8, 2016 - BioStable Science & Engineering, Inc. announced today the company has received CE Mark approval for the HAART 300 Aortic Annuloplasty [...]

March 8th, 2016|News, Press Release|